Sinopharm and China General Technology boost production, with deliveries running around the clock after the sudden reversal of ‘zero-Covid’

Drugmakers consider technology transfer to crank up production once the treatment wins regulatory approval

In the face of efficacy and safety concerns, China becomes the world’s top exporter of coronavirus shots as logistics companies ramp up flights

Organization’s validation of the shot’s safety, efficacy and quality paves the way for its broader rollout globally

Sinopharm’s Covid-19 vaccine moves closer to WHO nod for emergency use. Hong Kong has a new richest man

U.N. agency’s experts find 78.1% effectiveness for ages 18-59 but cite insufficient data for assessing the shot in people ages 60 and older or with underlying conditions

On visit by Foreign Minister Wang Yi, the two countries agree to a series of collaborative measures on health care

The figure represents a 15% increase on the previous week, but accounts for a far smaller proportion of the population than many developed nations

The scramble to crank out enough shots to inoculate more than 1 billion Chinese involves multiple companies pursuing different strategies and building massive factories

Humanity faces a rugged battle to make enough vaccines quickly enough, distribute them worldwide and get them into billions of people’s arms

Key things to know as mass vaccinations against Covid-19 pick up steam around the world in humanity’s best hope for corralling a pandemic

Limited publishing of clinical trial data by domestic Covid-19 vaccine developers suggests efficacy results vary widely, threatening to undermine public trust, says director of institute co-founded by the Gates Foundation

Vaccinations for people with higher coronavirus infection risks show no serious adverse effects, local authorities say

Sinopharm’s experimental inoculations for front-line workers become the first to be deployed abroad before completing clinical trials

Investors flock to Sinopharm and two units as human trials indicate experimental Covid-19 inoculation is safe and elicits antibodies

Sinopharm has begun the second phase of tests just 12 days after launching the first phase

$420 million investment in retail unit of Sinopharm Group is pharmacy giant’s biggest China purchase to date